Literature DB >> 6874737

Increased blood--brain barrier transport of protein-bound anticonvulsant drugs in the newborn.

E M Cornford, W M Pardridge, L D Braun, W H Oldendorf.   

Abstract

The extraction of heroin, caffeine, diphenylhydantoin, and phenobarbital has been measured in the newborn, suckling, and adult brain. Anticonvulsant drugs such as diphenylhydantoin and phenobarbital are bound by plasma protein, and it is generally believed that only the fraction of drug that is free (dialyzable) in vitro is available for transport through the blood-brain barrier in vivo. In both the adult and neonatal rat or rabbit, lipid-mediated transport of free phenytoin occurs. In addition, a fraction of the drug that enters the capillary bound to plasma protein also gains access to the brain. A greater amount of protein-bound drug permeates the newborn brain, and this is ascribed to a longer capillary transit time in the neonate. With regard to phenobarbital, the total (i.e., both free and protein-bound) plasma drug enters the newborn brain. In contrast, no protein-bound phenobarbital permeates the adult brain, and it is only the free drug fraction that gains access to the brain. Since the blood-brain barrier permeability-surface area product for the two anticonvulsants is unchanged in newborn and older animals, the age-related differences in brain uptake of protein-bound drugs can be attributed to developmental changes in cerebral blood flow and capillary transit time. The increased transport of protein-bound drugs in the newborn may cause increased concentrations (i.e., brain:plasma ratios) of these anticonvulsants in the neonatal brain.

Entities:  

Mesh:

Substances:

Year:  1983        PMID: 6874737     DOI: 10.1038/jcbfm.1983.42

Source DB:  PubMed          Journal:  J Cereb Blood Flow Metab        ISSN: 0271-678X            Impact factor:   6.200


  7 in total

Review 1.  Treating disorders of the neonatal central nervous system: pharmacokinetic and pharmacodynamic considerations with a focus on antiepileptics.

Authors:  Maria D Donovan; Geraldine B Boylan; Deirdre M Murray; John F Cryan; Brendan T Griffin
Journal:  Br J Clin Pharmacol       Date:  2015-11-04       Impact factor: 4.335

2.  Tracer kinetic model of blood-brain barrier transport of plasma protein-bound ligands. Empiric testing of the free hormone hypothesis.

Authors:  W M Pardridge; E M Landaw
Journal:  J Clin Invest       Date:  1984-09       Impact factor: 14.808

Review 3.  The myth of the immature barrier systems in the developing brain: role in perinatal brain injury.

Authors:  Carina Mallard; C Joakim Ek; Zinaida S Vexler
Journal:  J Physiol       Date:  2018-04-16       Impact factor: 5.182

4.  Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs.

Authors:  E M Cornford; D Young; J W Paxton
Journal:  Cancer Chemother Pharmacol       Date:  1992       Impact factor: 3.333

5.  Blood-brain barrier damage and brain penetration of antiepileptic drugs: role of serum proteins and brain edema.

Authors:  Nicola Marchi; Giulia Betto; Vincent Fazio; Quinyuan Fan; Chaitali Ghosh; Andre Machado; Damir Janigro
Journal:  Epilepsia       Date:  2009-01-21       Impact factor: 5.864

6.  Participation of Monocarboxylate Transporter 8, But Not P-Glycoprotein, in Carrier-Mediated Cerebral Elimination of Phenytoin across the Blood-Brain Barrier.

Authors:  Ryuta Jomura; Shin-Ichi Akanuma; Björn Bauer; Yukiko Yoshida; Yoshiyuki Kubo; Ken-Ichi Hosoya
Journal:  Pharm Res       Date:  2021-02-01       Impact factor: 4.200

7.  Computational investigations of physicochemical, pharmacokinetic, toxicological properties and molecular docking of betulinic acid, a constituent of Corypha taliera (Roxb.) with Phospholipase A2 (PLA2).

Authors:  Mohammad Firoz Khan; Nusrat Nahar; Ridwan Bin Rashid; Akhtaruzzaman Chowdhury; Mohammad A Rashid
Journal:  BMC Complement Altern Med       Date:  2018-02-02       Impact factor: 3.659

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.